Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Drug

CANbridge’s Maralixibat Receives Priority Review for PFIC Treatment in China

Fineline Cube Oct 17, 2023

China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced that a New Drug...

Company R&D

WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform

Fineline Cube Oct 17, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...

Company Drug

Fosun Pharma Initiates Phase III Trial for ET-26 Anesthetic in China

Fineline Cube Oct 17, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...

Company Drug

Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO

Fineline Cube Oct 16, 2023

China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech...

Policy / Regulatory

China’s 9th National VBP Round Sets Rules for 42 Drugs Tender

Fineline Cube Oct 16, 2023

The national drug alliance procurement office has issued a notification detailing the tendering rules for...

Company Drug

Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial

Fineline Cube Oct 16, 2023

China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...

Company Deals

Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development

Fineline Cube Oct 16, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company...

Company Drug

SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study

Fineline Cube Oct 16, 2023

SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it...

Company Deals

Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671

Fineline Cube Oct 16, 2023

China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly...

Company Deals

Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round

Fineline Cube Oct 16, 2023

Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai...

Company Drug

Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery

Fineline Cube Oct 16, 2023

China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...

Policy / Regulatory

NMPA Announces Pathway for Developing Generic Drugs Without Reference Preparation

Fineline Cube Oct 16, 2023

The National Medical Products Administration (NMPA) has issued an announcement regarding the development of generic...

Company

Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast

Fineline Cube Oct 16, 2023

Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a...

Company Deals

Shandong Saito Biotech to Acquire Majority Stake in Yingu Pharmaceutical

Fineline Cube Oct 16, 2023

China-based Shandong Saito Bio-Technology Co., Ltd. (SHE: 300583) has announced plans to acquire a 60%...

Company Drug

Pfizer’s Velsipity Approved by FDA for Ulcerative Colitis Treatment

Fineline Cube Oct 16, 2023

China-based pharmaceutical company Everest Medicines (HKG: 1952) announced that its licensing partner, Pfizer Inc. (NYSE:...

Policy / Regulatory

China’s New Drug Quality Management Measures to Take Effect in 2024

Fineline Cube Oct 16, 2023

The State Administration for Market Regulation (SAMR) has released the “Drug Operation and Use Quality...

Company

Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand

Fineline Cube Oct 16, 2023

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a...

Policy / Regulatory

Fujian’s Fourth Round VBP Seeks Public Feedback on Drug Procurement List

Fineline Cube Oct 16, 2023

The Fujian drug and device joint procurement center has published the “Fujian Fourth Round Drug...

Company Drug

FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC

Fineline Cube Oct 13, 2023

The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...

Policy / Regulatory

China Introduces Trial Measures for Science and Technology Ethics Review

Fineline Cube Oct 13, 2023

The National Health Commission, Ministry of Science and Technology, Ministry of Education, and eight other...

Posts pagination

1 … 484 485 486 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.